# Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes

> **NCT00237237** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 588 (—)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** vildagliptin

## Key facts

- **NCT ID:** NCT00237237
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-02
- **Final completion:** —
- **Target enrollment:** 588 (—)
- **Last updated:** 2017-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00237237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00237237, "Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00237237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*